Aescin-based topical formulation to prevent foot wounds and ulcerations in diabetic microangiopathy.
Impairment of the peripheral microcirculation in diabetic patients often leads to severe complications in the lower extremities, such as foot infections and ulcerations. In this study, a novel aescin-based formulation has been evaluated as a potential approach to prevent skin breaks and ulcerations by improving the peripheral microcirculation and skin hydration.



In this registry study, 63 patients with moderate diabetic microangiopathy were recruited. Informed participants freely decided to follow either a standard management (SM) to prevent diabetic foot diseases (n = 31) or SM associated with topical application of the aescin-based cream (n = 32). Peripheral microcirculatory parameters such as resting skin flux, venoarteriolar response and transcutaneous gas tension were evaluated at inclusion and after 8 weeks. In addition, several skin parameters of the foot area, such as integrity (as number of skin breaks/patients), hydration and content of dead cells were assessed at the defined observational study periods.



Improvements in cutaneous peripheral microcirculation parameters were observed at 8 weeks in both groups; however, a remarkable and significant beneficial effect resulted to be exerted by the aescin-based cream treatment. In fact, the microcirculatory parameters evaluated significantly improved in the standard management + aescin-based cream group, compared with baseline and with the standard management group. Similar findings were reported for skin parameters of the foot area.



The topical formulation containing aescin could represent a valid approach to manage skin wounds and prevent skin ulcerations in patients affected by moderate diabetic microangiopathy.
Department SMO Biotech, Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Italy. lu.giacomelli6@gmail.com.
S
S
Hu
G
G
Belcaro
M
M
Dugall
M
M
Hosoi
S
S
Togni
G
G
Maramaldi
L
L
Giacomelli
D000279:Administration, Cutaneous; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D017719:Diabetic Foot; D004928:Escin / Q000627:therapeutic use*; D005260:Female; D005528:Foot; D006801:Humans; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D012042:Registries; D012867:Skin
D004928:Escin